TransMedics Group Inc., a prominent biotechnology company operating within the Health Care sector, is set to disclose its fourth-quarter and full-year 2025 financial results on February 24, 2026. The company, listed on the Nasdaq and trading in USD, specializes in transplant therapy for end-stage organ failure patients across various disease states, primarily serving the United States market.
As of February 12, 2026, TransMedics Group Inc. closed at a price of $132.22. This closing price positions the company approximately midway between its 52-week low of $62.07, recorded on March 5, 2025, and its 52-week high of $150.42, achieved on November 30, 2025. The stock’s performance over the past year reflects a recovery from its low, indicating a moderate upside, though it remains below its peak value.
The company’s market capitalization stands at $4.44 billion, underscoring its significant presence in the biotechnology sector. TransMedics Group Inc. exhibits a price-to-earnings (P/E) ratio of 50.6, suggesting that the market values its earnings at a substantial premium compared to its peers. Additionally, the price-to-book (P/B) ratio of 12.99 indicates that investors are willing to pay a premium for the company’s book assets, reflecting confidence in its future growth prospects and operational capabilities.
Despite the absence of new headlines in the latest update, the anticipation surrounding the upcoming financial results highlights the market’s interest in TransMedics Group Inc.’s performance and strategic direction. The company’s focus on innovative transplant therapies continues to position it as a key player in addressing critical healthcare needs for patients with end-stage organ failure.
